Evidence-Based Approaches to Melasma Management

Understanding Melasma

Melasma is a common acquired pigmentary disorder characterised by symmetrical brown or grey-brown patches on sun-exposed areas of the face, particularly the cheeks, forehead, upper lip, and chin. Affecting primarily women (90 percent of cases) with Fitzpatrick skin types III-V, melasma is driven by a complex relationship of UV radiation, hormonal influences, genetic predisposition, and vascular factors. Its chronic, relapsing nature makes it one of the most challenging conditions in aesthetic dermatology.

Pathophysiology

Melasma involves hyperactive melanocytes producing excessive melanin, but the underlying biology is more complex than simple melanocyte overactivity. Key pathological features include increased melanocyte sensitivity to hormonal and UV stimulation, elevated expression of stem cell factor (SCF) and its receptor c-KIT, increased vascular density in affected skin (suggesting a vascular component), basement membrane disruption allowing melanin to drop into the dermis, and heightened mast cell activity promoting inflammation and melanogenesis.

Types of Melasma

Wood’s lamp examination can help classify melasma by depth. Epidermal melasma (enhanced under Wood’s lamp) is most responsive to topical treatment. Dermal melasma (not enhanced under Wood’s lamp) is less responsive and more persistent. Mixed melasma (partially enhanced) is the most common presentation.

First-line treatments

Broad-spectrum sun protection

Rigorous daily sun protection is the foundation of melasma management. SPF 50+ broad-spectrum sunscreen applied generously and reapplied every 2 hours is essential. Visible light (400-700nm) also stimulates melanogenesis, making iron oxide-containing tinted sunscreens particularly beneficial as they block visible light that standard UV filters do not address.

Topical depigmenting agents

The gold standard topical protocol is the modified Kligman formula: hydroquinone 4 percent plus tretinoin 0.05 percent plus fluocinolone acetonide 0.01 percent. Hydroquinone inhibits tyrosinase, tretinoin accelerates epidermal turnover and enhances hydroquinone penetration, and the corticosteroid reduces inflammation that can worsen pigmentation.

Hydroquinone-free alternatives include tranexamic acid (topical 3-5 percent or oral 250mg twice daily), cysteamine cream, azelaic acid 15-20 percent, kojic acid, and arbutin. Tranexamic acid, in particular, has strong emerging evidence for both topical and oral use in melasma management.

Procedural Treatments

Chemical Peels

Superficial peels (glycolic acid 30-50 percent, salicylic acid 20-30 percent) applied in a series of sessions accelerate epidermal turnover and enhance topical agent penetration. They should be used cautiously and conservatively, as aggressive peeling can worsen melasma through post-inflammatory hyperpigmentation.

Laser and light treatments

Laser treatment for melasma requires extreme caution. Low-fluence Q-switched Nd:YAG (laser toning) has shown benefit in some studies but carries risk of rebound hyperpigmentation and paradoxical darkening. Fractional non-ablative lasers (1540nm, 1550nm) may help by promoting dermal remodelling. IPL is generally not recommended as it can worsen melasma. The pulsed-wave mode of the Sylfirm X RF microneedling device shows promising results by targeting the abnormal basement membrane.

Microneedling

Microneedling at shallow depths (0.25-0.5mm) combined with topical tranexamic acid or vitamin C enhances product delivery and accelerates epidermal turnover without the inflammation risk of deeper treatments.

Emerging Treatments

Oral tranexamic acid

Low-dose oral tranexamic acid (250mg twice daily) inhibits plasmin-mediated melanocyte activation through multiple pathways. Meta-analyses show significant improvement in MASI scores compared to placebo. Contraindications include history of thromboembolism. Regular monitoring is advisable during treatment.

Cysteamine

A naturally occurring aminothiol that inhibits melanin synthesis through multiple mechanisms. Shows comparable efficacy to hydroquinone without the risk of ochronosis from long-term use. Available as a 5 percent topical cream.

Long-term management strategy

1. Establish rigorous sun protection including visible light blocking
2. Initiate topical depigmenting therapy (hydroquinone or alternatives)
3. Consider oral tranexamic acid for moderate-severe cases
4. Add gentle procedural treatments after 2-3 months of topical therapy
5. Transition to maintenance with non-hydroquinone agents after clearing
6. Continue sun protection indefinitely as melasma is a chronic condition

Frequently asked questions

Can melasma be cured?

Melasma is a chronic condition that can be effectively managed but rarely permanently cured. Long-term maintenance therapy and sun protection are essential to prevent recurrence.

Is laser treatment safe for melasma?

Laser treatment carries significant risk of worsening melasma. When used, only low-fluence settings with conservative protocols are appropriate, and only after establishing a stable topical regimen.

How long before I see improvement?

Topical therapy typically shows improvement within 8-12 weeks. Oral tranexamic acid may produce faster results in 4-8 weeks. Full clearing, if achievable, often requires 6-12 months of consistent treatment.